WHO rejects SII’s proposal seeking extension of Covishield’s shelf life from 6 to 9 months

The UN body has also sought a meeting with the Drugs Controller General of India to discuss the matter 10:12

Press Trust of India April 08, 2021 22:14:20 IST
WHO rejects SII’s proposal seeking extension of Covishield’s shelf life from 6 to 9 months

Representational image via PTI

New Delhi: The WHO has rejected Serum Institute of India's proposal seeking extension of the shelf life of Oxford-AstraZeneca COVID-19 vaccine, Covishield, from six to nine months, citing insufficient data, sources said.

The WHO has also sought a meeting with the Drugs Controller General of India (DCGI) to discuss the matter, they said.

The move comes even as India's drug regulator has extended Covishield's shelf life from six to nine months from its manufacturing date.

In a recent communique to Pune-based Serum Institute of India (SII), the WHO has also asked the firm to formulate the doses with enough titer and/or implement a higher specification at release so that the minimum specification of= 2.5 x108ifu/dose is fulfilled throughout the shelf life.

Shelf life is the length of time for which an item remains fit for use.

The DCGI in a letter to SII in February said it has no objection in respect of 'extension of shelf life of Covishield vaccine' in a multi-dose glass vial (10 dose-5ml) from six months to nine months.

"You are permitted to apply the shelf life of nine months to unlabelled vials available on hand, subject to the condition that the details of such stock, batch-wise, shall be submitted to this office and Central Drugs Laboratory, Kasauli," DCGI Dr V G Somani had said in the letter.

The DCGI's decision will help health authorities in reducing vaccine wastage.

According to an update by the UK drug regulator dated February 22, the shelf-life of the AstraZeneca COVID-19 vaccine is six months.

Meanwhile, concerns have been raised about the vaccine as the European Union's health agency concluded a "possible link" between the vaccine and rare blood clots but stressed that the benefits of the vaccine to protect against COVID-19 continue to outweigh the risks.

The UK's medicines regulator on Wednesday said that under-30s in the country will be offered an alternative to the Oxford-AstraZeneca vaccine due to "evolving evidence" linking it to rare blood clots.

Developed by Oxford University and Swedish-British pharma major AstraZeneca, Covishield is being manufactured by SII.

Updated Date:

also read

WHO COVID-19 origins report: What are WHO's four theories on the emergence of SARS-CoV-2?
science

WHO COVID-19 origins report: What are WHO's four theories on the emergence of SARS-CoV-2?

A joint statement by 14 countries states that they don't believe the conditions under which the report was written was "independent and objective".

China considering mixing different COVID-19 vaccines to improve efficacy of jabs, says top health official
World

China considering mixing different COVID-19 vaccines to improve efficacy of jabs, says top health official

Authorities have to "consider ways to solve the issue that efficacy rates of existing vaccines are not high", Chinese media outlet The Paper reported, citing Gao Fu, the head of the Center for Disease Control and Prevention

WTO says recovery of global trade in 2021 hinges on widespread COVID-19 vaccination
World

WTO says recovery of global trade in 2021 hinges on widespread COVID-19 vaccination

While the rebound this year will be stronger than expected, WTO's growth forecast states it could slow to 4 percent in 2022.